Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
Fiche du document
2012
- handle: 10670/1.ipnwn5
- 0036-3634
Ce document est lié à :
http://www.redalyc.org/revista.oa
Salud Pública de México
Mots-clés
Salud QALY Mexico antibodies monoclonal Cost effectivenessSujets proches
Synagis (Trademark)Citer ce document
Guillermo Salinas-Escudero et al., « Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico », Salud Pública de México, ID : 10670/1.ipnwn5
Métriques
Partage / Export
Résumé
"The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [